Insider Transactions in Q2 2024 at Syros Pharmaceuticals, Inc. (SYRS)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
34,837
-81.32%
|
$174,185
$5.12 P/Share
|
|
Jun 05
2024
|
Peter Wirth |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Marsha Fanucci |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Andrew M. Oh |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Sue Gail Eckhardt |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Timothy Tyson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+10.76%
|
-
|
|
Jun 05
2024
|
Richard A Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+8.54%
|
-
|
|
Jun 05
2024
|
Nancy A Simonian |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+2.86%
|
-
|
|
Jun 01
2024
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+37.5%
|
-
|
|
Jun 01
2024
|
Deborah Dunsire |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+25.0%
|
-
|
|
Apr 03
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,451
-100.0%
|
$41,804
$4.95 P/Share
|
|
Apr 02
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
150
-1.42%
|
$600
$4.98 P/Share
|
|
Apr 01
2024
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
14,052
-9.64%
|
$70,260
$5.12 P/Share
|
|
Apr 01
2024
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,218
-14.32%
|
$21,090
$5.12 P/Share
|
|
Apr 01
2024
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,732
-16.16%
|
$23,660
$5.12 P/Share
|
|
Apr 01
2024
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,732
-30.86%
|
$23,660
$5.12 P/Share
|
|
Apr 01
2024
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,500
-13.46%
|
$17,500
$5.12 P/Share
|